Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study
Gut and Liver · 15.07.2026 · 20 (4) · 624-635
DOI: 10.5009/gnl250532 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 07.04.2026. Verfasst von Yuri Cho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
- Biostatistics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea.
ORCID-Profile: Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park
Zitieren
APA
Cho, Y., Lee, J. H., Ryoo, B. Y., Lim, H. Y., Lee, D. E., Kim, B. H., & Park, J. W. (2026). Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study. Gut and Liver, 20(4), 624-635. https://doi.org/10.5009/gnl250532
Vancouver
Cho Y, Lee JH, Ryoo BY, Lim HY, Lee DE, Kim BH, et al. Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study. Gut and Liver. 2026;20(4):624-635. doi:10.5009/gnl250532
BibTeX
@article{Cho2026,
author = {Cho, Yuri and Lee, Jeong-Hoon and Ryoo, Baek-Yeol and Lim, Ho Yeong and Lee, Dong Eun and Kim, Bo Hyun and Park, Joong-Won},
title = {Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study},
journal = {Gut and Liver},
year = {2026},
volume = {20},
number = {4},
pages = {624--635},
doi = {10.5009/gnl250532}
}
EUVIMED